Rhythm Pharmaceuticals, Inc.

Sarepta Therapeutics, buoyed at the start of 2025 by rapidly rising sales of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), is now sinking from the finan

Rhythm Pharmaceuticals plans to build out its sales force to target endocrinologists as it looks ahead to filing for US Food and Drug Administration approval of setmelanotide in acquired hypothalamic

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron